GP
Geoffrey Porges SVB Leerink Latest Price Targets & Analyst Ratings
| Stock | Price | Price Target |
Upside Downside | Rating | Date | |
|---|---|---|---|---|---|---|
1
Pfizer
PFE
$140B
| $24.59 | $56 |
128%
upside
| Market Perform |
15 Dec ‘21
3 years ago |
|
2
Arcus Biosciences
RCUS
$1.25B
| $11.72 | $100 |
753%
upside
| Outperform |
18 Nov ‘21
3 years ago |
|
3
Regeneron Pharmaceuticals
REGN
$58.9B
| $555.44 | $850 |
53%
upside
| Outperform |
5 Nov ‘21
3 years ago |
|
4
Halozyme
HALO
$8.86B
| $75.79 | $48 |
37%
downside
| Outperform |
3 Nov ‘21
3 years ago |
|
5
Amgen
AMGN
$150B
| $278.49 | $216 |
22%
downside
| Market Perform |
3 Nov ‘21
3 years ago |
|
6
AbbVie
ABBV
$374B
| $211.66 | $135 |
36%
downside
| Outperform |
1 Nov ‘21
3 years ago |
|
7
Roivant Sciences
ROIV
$9.4B
| $13.77 | $11 |
20%
downside
| Outperform |
1 Nov ‘21
3 years ago |
|
8
Gilead Sciences
GILD
$143B
| $115.25 | $75 |
35%
downside
| Outperform |
29 Oct ‘21
3 years ago |
|
9
Theravance Biopharma
TBPH
$688M
| $13.66 | $10 |
27%
downside
| Outperform |
16 Sep ‘21
4 years ago |
|
10
FibroGen
FGEN
$47.1M
| $11.65 | $750 |
6,338%
upside
| Outperform |
10 Aug ‘21
4 years ago |
|
11
Vertex Pharmaceuticals
VRTX
$99.6B
| $388.42 | $175 |
55%
downside
| Underperform |
30 Jul ‘21
4 years ago |
|
12
Assembly Biosciences
ASMB
$170M
| $22.20 | $84 |
278%
upside
| Market Perform |
10 May ‘21
4 years ago |
|